Skip to main content
Sunday
September 08, 2024
Sign In
Subscribe
Home
Epaper
Economy
Aviation
Banking
Bazaar
Budget
Industry
NBR
RMG
Corporates
Stocks
Analysis
Videos
Podcast
World+Biz
Features
Book Review
Brands
Earth
Explorer
Food
Habitat
In Focus
Luxury
Mode
Panorama
Pursuit
Wheels
Subscribe
Epaper
GOVT. Ad
More
Sports
TBS Graduates
Thoughts
Splash
Bangladesh
Supplement
Infograph
Archive
Gallery
Long Read
Interviews
Offbeat
Tech
Magazine
Climate Change
Health
Cartoons
বাংলা
SUNDAY,
SEPTEMBER 08, 2024
Johnson & Johnson Covid-19 Vaccine
World+Biz
J & J expects up to $3.5 bln in Covid vaccine sales this year
Coronavirus chronicle
Johnson booster 85% effective against Omicron: S Africa study
Coronavirus chronicle
US CDC advisers to weigh limits on J&J vaccine due to blood clot issues -Washington Post
Coronavirus chronicle
US brokers J&J-COVAX deal to send vaccines to conflict zones -Blinken
Coronavirus chronicle
J&J says second shot boosts protection for moderate-severe Covid-19 to 94%
Coronavirus chronicle
India set to get first J&J Covid vaccine doses in October, says source
Coronavirus chronicle
Key data on US J&J, Moderna Covid-19 boosters weeks away, Fauci says
Coronavirus chronicle
Second dose of J&J vaccine gives strong boost, says company report
Coronavirus chronicle
South Africa study shows high Covid protection from J&J vaccine
Coronavirus chronicle
Johnson & Johnson applies for approval of its single-dose Covid vaccine in India
Coronavirus chronicle
J&J says still in talks with Indian govt on Covid-19 vaccine
Coronavirus chronicle
J&J withdraws accelerated approval of its Covid vaccine in India
Coronavirus chronicle
EU lists rare nerve disorder as side-effect of J&J Covid-19 vaccine
Show More